Clinical Trial Update: Multicentre, Randomized, Prospective Trial Evaluating the Efficacy and Safety of Infliximab to Tocilizumab in Refractory or Relapsing Takayasu Arteritis [Phase 2]

View source ↗

Summary

A multicenter randomized Phase 2 trial evaluating infliximab versus tocilizumab in refractory or relapsing Takayasu arteritis is ongoing with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Takayasu Arteritis

Drugs mentioned

• Infliximab (infliximab)
• Tocilizumab (tocilizumab)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Takayasu Arteritis | Phase 2 | Status: UNKNOWN